Evgen Pharma PLC Positive pre-clinical data for lead asset SFX-01 (3802M)
January 21 2021 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 3802M
Evgen Pharma PLC
21 January 2021
Evgen Pharma plc
("Evgen" or the "Company")
Positive pre-clinical data in Glioma for lead asset SFX-01
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company, announces that its collaboration with a prominent European
university has generated highly positive data for SFX-01 in
pre-clinical models of glioma and glioblastoma.
Glioma is the most common form of brain tumour affecting around
5 per 100,000 people. The more severe, grade IV classification,
glioblastoma, is a very serious form of brain tumour representing
45% of all cases and has a poor prognosis with median survival of
around 14 months. The five-year survival of the severe grades is
5%.
The data generated for SFX-01 in standard pre-clinical models
and orthotopic models (where glioma cells are implanted in brain
tissue representing a more disease-relevant model) show tumour
shrinkage and significantly extended survival times. SFX-01 was
also found to potentiate (i.e. substantially increase) the
therapeutic effect of radiotherapy in these models.
The therapeutic options for glioma are limited to surgery,
radiotherapy and the one drug widely available, temozolomide. There
is a clear unmet need for more treatments for use in conjunction
with the current standard of care.
Dr Huw Jones, Evgen CEO, commented: "We are excited by this
compelling new data in a type of cancer which has severely limited
therapeutic options for the patient. The positive tolerability
profile of SFX-01 makes it a viable option for use in addition to
current treatments. Our plan is to expand upon these pre-clinical
data in this and new collaborations, and start the process of
designing an appropriate Phase II clinical trial."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Barry Clare, Chairman
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDBLFLFFLEBBB
(END) Dow Jones Newswires
January 21, 2021 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024